It's not developing drugs that bind to RNA, or morphing RNA into a therapeutic — this Cambridge startup has scored $63M to work on RNA-modifying proteins

As researchers found that chemical modifications across a cell’s RNA were seemingly distorted in some cancers, a trio of biotechnology companies spawned: Storm Therapeutics, Accent Therapeutics and Gotham Therapeutics. On Thursday, 2017-founded Accent raised $63 million in a Series B round, led by EcoR1 Capital.